Opendata, web and dolomites

StaphIMPACT SIGNED

SA.100: Next-generation targeted antibacterial product entering European market

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 StaphIMPACT project word cloud

Explore the words cloud of the StaphIMPACT project. It provides you a very rough idea of what is the project "StaphIMPACT" about.

2050    companies    produces    first    resistant    pharma    8b    cancer    100    caused    care    communication    alternatives    soft    resistance    antibacterial    deaths    acne    antibiotics    final    staphylococcus    replace    kols    compounds    diabetic    roll    health    innovation    small    chosen    aggravated    hyper    biggest    develops    triggered    expressed    according    trillion    infections       cagr    177b    us    markets    facilities    sa    people    thousands    netherlands    license    world    unless    eczema    secured    dermatology    time    threats    driving    rosacea    brand    full    regardless    2023    ige    prepares    helping    launched    19    million    aureus    bacteria    contribution    company    2024    inflammatory    micreos    antibiotic    wound    2018    life    endolysin    indications    clinical    gladskin    mrsa    syndrome    suffering    kill    extra    10    claiming    cosmetics    skin    ideas    profitability    smei    changing    owns    employment    stakeholders    capacity    market       ip    humanity    kills   

Project "StaphIMPACT" data sheet

The following table provides information about the project.

Coordinator
MICREOS HUMAN HEALTH BV 

Organization address
address: BANKAPLEIN 2
city: S GRAVENHAGE
postcode: 2585EV
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 3˙565˙625 €
 EC max contribution 2˙495˙937 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MICREOS HUMAN HEALTH BV NL (S GRAVENHAGE) coordinator 2˙495˙937.00

Map

 Project objective

According to the WHO, antibiotic resistance is one of humanity’s biggest health threats, claiming ~10 million extra deaths per year and US$100 trillion by 2050, unless alternatives to antibiotics are developed. Micreos has developed the world’s first targeted antibacterial products, set to replace antibiotics. With its endolysin technology, for the first time it is possible to kill only the unwanted bacteria, regardless of resistance. Micreos’ endolysin technology was chosen as Europe’s most relevant Innovation 2018 (Ideas from Europe). Its first lead endolysin, SA.100, kills only Staphylococcus aureus, including the resistant MRSA. Soft-launched under the Gladskin brand in the Netherlands, it’s having life-changing impact for thousands of people with inflammatory skin conditions caused or aggravated by S. aureus, including eczema, acne, rosacea and Hyper IgE syndrome. Micreos also develops products for diabetic wound infections and a skin cancer triggered by S. aureus. Micreos owns all relevant IP and know-how on its technology and produces its compounds and Gladskin products at small-scale at its facilities in the Netherlands. With this SMEi, Micreos prepares for full roll-out into the EU markets of its SA.100/Gladskin. This includes scale-up of production capacity, strengthening clinical evidence and communication of results to KOLs and relevant stakeholders. Leading pharma and cosmetics companies have expressed interest to in-license Micreos’ technology for particular indications. Relevant markets are the consumer’s skin care market ($177b by 2024; CAGR 4.7%) and dermatology market ($19.8b by 2023; CAGR 9.1%.). Own contribution by Micreos for this SMEi is already secured. This SMEi enables Micreos to take final steps for EU-wide roll-out, driving employment growth and company profitability, and helping people suffering from inflammatory skin conditions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STAPHIMPACT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STAPHIMPACT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

ChromicGlass (2019)

FAST-RESPONSIVE and LONG-LASTING TRANSPARENT PHOTOCHROMIC FILMS

Read More  

NAAS (2019)

NaaS - Newsroom as a service

Read More